Welcome to our dedicated page for Predictive Oncology news (Ticker: POAI), a resource for investors and traders seeking the latest updates and insights on Predictive Oncology stock.
Predictive Oncology Inc. (NASDAQ: POAI) is at the forefront of using data and artificial intelligence (AI) to create personalized cancer treatments, aiming for more effective therapies and better patient outcomes. The company's mission revolves around precision medicine in cancer diagnosis, leveraging several key resources:
- Database: A comprehensive database of clinically validated historical and outcome data from patient tumors.
- CLIA-Certified Lab: An in-house Clinical Laboratory Improvement Amendments (CLIA) certified lab.
- Smart Tumor Profiling: A patient-derived tumor profiling platform that offers intelligent insights.
- Bioinformatics AI Platform: An advanced AI platform for in-house bioinformatics.
- Innovative Tumor Growth: Techniques for growing tumors in the lab to rapidly develop patient-specific treatment options.
- FDA-Approved System: The FDA-approved STREAMWAY System for automated medical fluid waste management.
Predictive Oncology's business is structured across three main segments:
- Pittsburgh Segment: Focuses on AI applications using a proprietary biobank with over 150,000 tumor samples and creates 3D culture models for drug development.
- Birmingham Segment: Provides contract research services targeting solubility improvements, stability studies, and protein production.
- Eagan Segment: Produces the FDA-cleared STREAMWAY System for medical fluid disposal, driving the majority of the company's revenue.
Recent achievements highlight the company's collaborative efforts with pharmaceutical, diagnostic, and biotech industries:
- Hosted an investor call and webcast on November 14th, providing insights into future strategies and financial performance.
- Presented a study in collaboration with UPMC Magee-Womens Hospital, utilizing AI to predict ovarian cancer survival outcomes better than clinical data alone.
- Announced a partnership with FluGen to develop a stable intranasal flu vaccine, leveraging Predictive Oncology’s biologics capabilities.
- Unveiled a proprietary 3D cell culture model to enhance cancer drug discovery.
- Introduced a new platform for functional and stable G-Protein Coupled Receptors (GPCRs), targeting advancements in cancer therapeutics.
Predictive Oncology's AI platform, PEDAL, has been validated to predict tumor sample responses to drug compounds with 92% accuracy. This platform, combined with the company's biobank of over 150,000 tumor samples and CLIA lab facilities, positions Predictive Oncology as a leader in AI-driven drug discovery and development.
News
Rhea-AI Summary
Predictive Oncology Inc. (NASDAQ: POAI) completed a multi-year study with UPMC Magee-Womens Hospital, using AI-driven machine learning models to evaluate associations between datasets and ovarian cancer patient survival. The study incorporated one of the largest sets of multi-omic data from 235 ovarian cancer patients, aiming to identify key features driving overall survival endpoints. The AI-driven models have the potential to tailor therapies to individual patients, positively affecting the overall survival of ovarian cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
-
Rhea-AI Summary
Predictive Oncology Inc. (NASDAQ: POAI) will report its financial results for the third quarter ended September 30th, 2023 before the markets open on Tuesday, November 14, 2023. The company will host a corporate update conference call and live audio webcast at 8:30 a.m. on that day. The webcast replay will be available in the Investors section of the Predictive Oncology website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
-
Rhea-AI Summary
Predictive Oncology (POAI) reported a net loss of $3.9 million on total net revenue of $0.5 million for the second quarter of 2023. The company initiated strategic collaborations, delivered a presentation at the Bio International Convention, and relocated its corporate headquarters to Pittsburgh, PA. Predictive Oncology's financial summary for Q2 2023 includes $14.8 million in cash and cash equivalents, $14.7 million in Stockholder’s Equity, and a loss per common share of $0.98. The company recorded revenue of $490,110 in Q2 2023, with gross profit margin increasing to 67%. However, G&A expenses, operations expenses, and sales and marketing expenses all increased compared to the same period in 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.01%
Tags
-
Rhea-AI Summary
Predictive Oncology Inc. (NASDAQ: POAI) announced the relocation of its corporate headquarters to its main laboratory facility in Pittsburgh, PA, a global life sciences hub. The move reinforces the company’s commitment to scientific discovery and growth potential, leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory, and Good Manufacturing Practices (GMP) facility. The new location in Pittsburgh further solidifies the company's footprint and expansion of the laboratory and center for artificial intelligence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.97%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.88%
Tags
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.93%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.88%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.12%
Tags
FAQ
What is the current stock price of Predictive Oncology (POAI)?
The current stock price of Predictive Oncology (POAI) is $0.6526 as of November 20, 2024.
What is the market cap of Predictive Oncology (POAI)?
The market cap of Predictive Oncology (POAI) is approximately 4.3M.
What does Predictive Oncology Inc. specialize in?
Predictive Oncology Inc. specializes in using data and AI to develop personalized cancer therapies, improving treatment effectiveness and patient outcomes.
What are the key segments of Predictive Oncology’s business?
The key segments are Pittsburgh (AI applications and biobank), Birmingham (contract research services), and Eagan (medical fluid disposal systems).
What recent collaborations has Predictive Oncology announced?
Recent collaborations include a study with UPMC Magee-Womens Hospital, and a partnership with FluGen for a stable intranasal flu vaccine.
How accurate is Predictive Oncology’s AI platform PEDAL?
PEDAL can predict with 92% accuracy if a tumor sample will respond to a specific drug compound.
What is the significance of Predictive Oncology’s 3D cell culture model?
The 3D cell culture model closely mimics human tissue, providing better predictions of clinical outcomes and optimizing drug candidate selection.
How does Predictive Oncology’s STREAMWAY System benefit the healthcare industry?
The STREAMWAY System offers automated medical fluid waste management, improving safety and efficiency in medical fluid disposal.
What are GPCRs and why are they important in cancer treatment?
GPCRs are cell surface receptors involved in cancer progression. Predictive Oncology’s new technology aims to enhance drug discovery targeting GPCRs.
What is Predictive Oncology’s biobank?
Predictive Oncology's biobank contains over 150,000 tumor samples, providing a robust resource for AI-driven drug discovery and development.
Where is Predictive Oncology headquartered?
Predictive Oncology is headquartered in Pittsburgh, PA.
Who can I contact for investor relations at Predictive Oncology?
For investor relations, contact Tim McCarthy at LifeSci Advisors, LLC via email at tim@lifesciadvisors.com.
Predictive Oncology Inc.
Nasdaq:POAI
POAI Rankings
POAI Stock Data
4.33M
6.52M
2.16%
4.01%
2.23%
Medical Instruments & Supplies
Orthopedic, Prosthetic & Surgical Appliances & Supplies
United States of America
PITTSBURGH